SCHEMBL875166

SCHEMBL875166

N[C@@H](CCCCNC(=O)C(F)(F)F)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.62
POLB P06746 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
CA3 P07451 2/20 0.55
CA5A P35218 2/20 0.55
CA5B Q9Y2D0 2/20 0.55
CA12 O43570 1/20 0.55
CA2 P00918 1/20 0.55
CA4 P22748 1/20 0.55
CA6 P23280 1/20 0.55
CA7 P43166 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
EPHX1 P07099 1/20 0.51
GSR P00390 1/20 0.48
OTC P00480 1/20 0.47
ARG2 P78540 4/20 0.44
ARG1 P05089 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604188 1.00 ALDH1A1 (0.62) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL6033129 1.00 ALDH1A1 (0.62) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL22679808 0.95 ALDH1A1 (0.59) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL31296029 0.95 ALDH1A1 (0.59) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL23728668 0.93 ALDH1A1 (0.57) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL23728666 0.93 ALDH1A1 (0.57) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL7322492 0.90 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL29361453 0.83 GSR (0.46) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL26692311 0.83 OTC (0.49) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL21689955 0.83 GSR (0.48) GSROTCARG2ARG1DDAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042739-A1 Formation of N-Protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine MANNKIND CORP (US) 2026-02-12 US claimed
US-20250163003-A1 Formation of N-Protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2025-05-22 US claimed
US-20240269301-A1 METHOD FOR INITIATING POLYMERIZATION OF AMINO ACID N-CARBOXYANHYDRIDES IN AQUEOUS PHASE PEKING UNIVERSITY (CN) 2024-08-15 US claimed
US-12018057-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases JANSSEN BIOTECH, INC. (US) 2024-06-25 US claimed
CN-117776978-A Preparation method of N epsilon- [ (9H-fluorene-9-ylmethoxy) carbonyl ] -L-lysine derivative 长兴宜生药物科技有限公司 2024-03-29 CN claimed
US-20240092830-A1 PROCESS FOR PREPARING CARBOXYL CYCLIC ACID ANHYDRIDE PEKING UNIVERSITY (CN) 2024-03-21 US claimed
EP-4321179-A1 METHOD FOR INITIATING POLYMERIZATION OF AMINO ACID N-CARBOXYANHYDRIDES IN AQUEOUS PHASE Peking University (CN) 2024-02-14 EP claimed
EP-4265600-A1 PROCESS FOR PREPARING CARBOXYL CYCLIC ACID ANHYDRIDE Peking University (CN) 2023-10-25 EP claimed
CN-116670120-A Process for preparing carboxylic cyclic anhydride 北京大学 2023-08-29 CN claimed
US-20220402983-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES JANSSEN BIOTECH, INC. 2022-12-22 US claimed
EP-1807467-B1 PROCESSES FOR PREPARING GLATIRAMER SANDOZ AG (CH) 2009-08-26 EP claimed
EP-2013628-A2 METHODS OF EVALUATING PEPTIDE MIXTURES Momenta Pharmaceuticals, Inc. (US) 2009-01-14 EP claimed
US-20080021200-A1 Processes for preparing a polypeptide SANDOZ AG (CH) 2008-01-24 US claimed
WO-2007127977-A2 METHODS OF EVALUATING PEPTIDE MIXTURES MOMENTA PHARMACEUTICALS, INC. (US) 2007-11-08 WO claimed
CN-101044188-A Process for preparing glatiramer SANDOZ AG (CH) 2007-09-26 CN claimed
EP-1807467-A1 PROCESSES FOR PREPARING GLATIRAMER Sandoz AG (CH) 2007-07-18 EP claimed
US-20060154862-A1 Processes for preparing a polypeptide SANDOZ AG (CH) 2006-07-13 US claimed
WO-2006050122-A1 PROCESSES FOR PREPARING GLATIRAMER SANDOZ AG (CH) 2006-05-11 WO claimed
EP-0239062-B1 N2-(1-CARBOXY-3-OXO-3-PHENYLPROPYL)-L-LYSINE COMPOUNDS AND THEIR DERIVATIVES KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1991-05-29 EP claimed
EP-0239062-A2 N2-(1-carboxy-3-oxo-3-phenylpropyl)-L-Lysine compounds and their derivatives KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-09-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042739-A1 Formation of N-Protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine ACMSD, DNPEP, PGM2 ALDH1A1 4060/4885POLB 1629/4885SMN1; SMN2 4316/4885
US-20250163003-A1 Formation of N-Protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine PGM2, DNPEP, NPEPPS ALDH1A1 4131/4885POLB 1165/4885SMN1; SMN2 4734/4885
US-20220402983-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES IL23R, IL1RN, VIP ALDH1A1 4574/4885POLB 4308/4885SMN1; SMN2 4301/4885
US-20240092830-A1 PROCESS FOR PREPARING CARBOXYL CYCLIC ACID ANHYDRIDE CA9, CA7, APEH ALDH1A1 347/4885POLB 1218/4885SMN1; SMN2 4051/4885
US-20240269301-A1 METHOD FOR INITIATING POLYMERIZATION OF AMINO ACID N-CARBOXYANHYDRIDES IN AQUEOUS PHASE DNPEP, DAO, BCAT1 ALDH1A1 3280/4885POLB 345/4885SMN1; SMN2 2509/4885
US-12018057-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases IL23R, IL1RN, VIP ALDH1A1 4574/4885POLB 4308/4885SMN1; SMN2 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.